Friday, August 18, 2017 5:17:24 PM
1. Nantcell now own all responsibility for getting approval and commercializing Aldo.
2. Not directly provable but I believer Dr Soon told CYTR to re-apply to the shareholder to enact the RS. This is clear buy his clear statement that he will support it with all his shares owned.
3. It is clear now that Dr Soon does NOT want to see his $13 mil investment depreciate anytime soon (sic) there for he has put the hammer down.
4. KMan is no longer in full control.
If the other tutes see it Dr Soon's way then yes, expect a huge rise on Monday. First reaction to this news and the hope that the delisting will be avoided Second, the result of the vote if it is positive.
Warning: The RS ratio has not been stated however I doubt whether it will be more than 1 to 5 given which would give a pps of around $2.75 which should keep the pps over $1.00 for over 10 business days.
Go $Cytr
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM